Cardiff Oncology

CRDFNasdaq United States Health Care Biotechnology: Biological Products (No Diagnostic Substances)

Market cap

$77.165 M

$0.99 +3.28%

Close of 7 Aug 2026

Revenue

$593.0K

#3544 by revenue

Earnings

-$45.9K

Loss-making

Shares outstanding

68,369,896

Latest filing cover page

P/E ratio

—

Cap ÷ net income

Biotechnology: Biological Products (No Diagnostic Substances) — ranked by market cap

All 160 →

#114Kalaris TherapeuticsKLRS$96.8M
#115Cognition TherapeuticsCGTX$96.7M
#116Cardiff OncologyCRDF$77.2M
#117Atara BiotherapeuticsATRA$76.1M
#118LeonaBioLONA$72.1M

Where these numbers come from

Share counts and financials for Cardiff Oncology are taken from its own SEC filings via EDGAR — public record, not an estimate. Market cap is shares outstanding multiplied by the latest close. Last updated 9 Aug 2026. Read the methodology.